Jennifer Martin and Dan Rogers Added to the Omnia Medical Team: Martin to Lead the Interventional Pain Therapies Division Alongside Thomas Batton and Dan Rogers

December 30, 2020

Jennifer Martin and Dan Rogers have been added to the Omnia Medical team.

Jennifer Martin will lead Omnia Medical’s Interventional Pain Therapies Division alongside Thomas Batton and Dan Rogers.

The new team members will be crucial in the expansion of Omnia Medical and the launch of a new division created for the sole focus of helping Pain Management Specialists provide leading-edge care to patients with debilitating pain due to Sacroiliac (SI) joint dysfunction.

Jennifer Martin, President of the new Interventional Pain Therapies division, brings over 15 years of experience in product training and market development. Most recently she served as Senior Director of Customer Engagement at Boston Scientific. Prior to her time at Boston Scientific, she served as CEO of Next Level Interactive, Sr. Director of Field and Physician Development at St. Jude Medical, and Vice President of Global Sales Training at KCI Medical.

Ms. Martin will be working closely with Dan Rogers as he joins Omnia Medical as the Vice President of Sales for the new division. He most recently served as Regional Sales Director at Boston Scientific and Vertiflex. With more than a decade of experience, Dan Rogers will join Thomas Batton and Sean Herd in working closely with Ms. Martin to grow and further advance technologies within the Interventional Pain Therapies division.

“I am incredibly excited to join Omnia Medical. The Company has a unique opportunity to accelerate an already impressive growth trajectory and become the posterior SI joint fusion system of choice for interventional pain management physicians and spine surgeons. I look forward to working with our Omnia Medical team and applying my experience and deep understanding of market development and growth for medical device companies.” – Jennifer Martin, President of Omnia Medical’s Interventional Pain Therapies division.

This new division will provide a strong collaboration between Spine Surgeons and Pain Management Specialists when diagnosing accurate patient pathology as spine related or SI joint dysfunction. This collaboration will further provide an opportunity for Pain Management Specialists to integrate SI joint fusion technologies in their treatment algorithm for patients.

The launch of the new division comes at a critical time when providers are increasingly focused on delivering a more comprehensive range of therapies. Omnia Medical is combining its research and development expertise with manufacturing experience to provide minimally invasive solutions tailored specifically to Pain Management Specialists.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.